Jorge Plutzky, M.D.,
Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals' Board of Directors
April 09, 2015 08:45 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Reaches Agreement With Sarissa Capital
March 30, 2015 08:30 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 30, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
March 10, 2015 16:25 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Observes Rare Disease Day
February 28, 2015 07:15 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
February 26, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 - - Company generates $17.9 million in positive cash flow from operations in the...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference
February 25, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2014 Financial Results on Thursday, February 26
February 12, 2015 07:55 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
February 10, 2015 16:45 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
February 05, 2015 16:10 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
January 13, 2015 20:30 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...